The guidance of EBITDA being up 12% was like for like. They only settled on their 3 acquisitions in mid October 2015 so they only contributed for 2.5 months of that period. As per the footnote in their release:
FY16 Q1 EBITDA used in the year on year comparison has been
adjusted to include FY16 Q1 EBITDA for Designs for Vision,
Western Biomedical and Meditron which were acquired in
October 2015.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $629.0M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 39.0¢ | 38.0¢ | $26.18K | 68.54K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 314858 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 28545 | 1 |
View Market Depth
| Last trade - 15.59pm 25/07/2025 (20 minute delay) ? |
| PGC (ASX) Chart |